Cargando…
The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs
Autores principales: | Bendicksen, Liam, Kesselheim, Aaron S., Rome, Benjamin N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Chest Physicians. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353103/ https://www.ncbi.nlm.nih.gov/pubmed/35940656 http://dx.doi.org/10.1016/j.chest.2022.02.048 |
Ejemplares similares
-
Family Calls and Visitation in the COVID-19 Era
por: Zaidi, Danish
Publicado: (2021) -
The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
por: Kesselheim, Aaron S., et al.
Publicado: (2012) -
Anticipated efficiencies, real costs: Medicaid managed care organizations and the pharmacy benefit
por: Bendicksen, Liam, et al.
Publicado: (2022) -
Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021
por: Deshmukh, Anjali D., et al.
Publicado: (2023) -
Microbiological contamination in counterfeit and unapproved drugs
por: Pullirsch, Dieter, et al.
Publicado: (2014)